Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
52.94
-0.01 (-0.02%)
At close: Apr 28, 2026, 4:00 PM EDT
52.90
-0.04 (-0.08%)
Pre-market: Apr 29, 2026, 4:00 AM EDT
Terns Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
6.11B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 812.03M |
| Rhythm Pharmaceuticals | 189.76M |
| Protagonist Therapeutics | 46.02M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 4.04M |
TERN News
- 1 day ago - Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia - GlobeNewsWire
- 4 days ago - Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. - Business Wire
- 13 days ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 21 days ago - Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review - Benzinga
- 21 days ago - Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc. - Business Wire
- 26 days ago - Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 4 weeks ago - Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
- 4 weeks ago - Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline - CNBC